Search Results 1761-1770 of 19458 for hemoglobin

  1. Neurosurgery - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  2. A Study to Evaluate the Effectiveness and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - Mayo Clinic

    Hemoglobin | ≤ 9.0 g/dL (transfusion allowed with 2-week washout period);; ANC | ≤ 1.5 × 109/L. Hepatic. ALT | > 2.5 × ULN (> 5 × ULN if related to ...

  3. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease - Mayo Clinic

    Hemoglobin ≥ 8 g/dL (both males and females);; Absolute neutrophil count (ANC) ≥1.5 × 10^9/L (1,500/mm^3);; Platelets ≥ 100 × 10^9/L;; White blood cells ...

  4. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies - Mayo Clinic

    Hemoglobin ≥ 8.0 g/dL within first 2 weeks prior to first dose of toripalimab;; Absolute neutrophil count (ANC) ≥ 1.2 x 10^9/L (1,200/mm^3);; Platelet count ...

  5. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma - Mayo Clinic

    Hemoglobin: ≥ 10 g/dL (transfuse as necessary to raise levels; no transfusions within 7 days of start). Adequate renal and hepatic function within 30 days ...

  6. Efficacy And Safety Of Subcutaneous Dupilumab In Participants With Asthma/asthmatic Wheeze Aged 2 To <6 Years - Mayo Clinic

    Examples include but are not limited to participants with short life expectancy, participants with uncontrolled diabetes (hemoglobin A1c ≥ 9%), severe ...

  7. A Study to Compare Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients - Mayo Clinic

    Hemoglobin ≥9.0 g/dL Absolute neutrophil count ≥1.0 × 109/L Platelet count ≥75 × 109/L Serum bilirubin ≤1.5 × the upper limit of normal (ULN) ...

  8. Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer - Mayo Clinic

    Hemoglobin ≥ 9 g/dL;; Chemistries as follows: Potassium ≥ lower limit of normal (LLN) range for the institution;; Calcium ≥ LLN (corrected for serum ...

  9. Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery - Mayo Clinic

    Hemoglobin ≥ 9 g/dL; Platelets ≥ 100 x 10^9/L; Albumin ≥ 2.5 g/dL; Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); Aspartate ...

  10. Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL or 5.6 mmol/L. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN unless participant is receiving ...